Active Clinical Trials
Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.
- Sort by Sort ascending
- Study title
- Condition
- Phase
- Location
| Study title | Condition | Phase | Location | |
|---|---|---|---|---|
Asciminib Roll-over Study |
Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Phase4 | Austria Brazil Bulgaria Canada China Czechia Denmark France Germany Italy Korea, Republic of Mexico Poland Romania Russian Federation Spain Turkey United Kingdom United States View All |
NCT04877522 |
Asciminib RMP Study |
Chronic Myeloid Leukemia | Korea, Republic of | NCT05943522 | |
A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea |
Non-Small-Cell Lung Carcinoma | Korea, Republic of | NCT05703516 | |
Specified Drug-use Survey of Leqvio for s.c. Injection. |
Familial Hypercholesterolaemia, Hypercholesterolaemia | Japan | NCT06275724 | |
CAR-T Long Term Follow Up (LTFU) Study |
Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program | Phase3 | Australia Austria Belgium Canada Denmark Finland France Germany Israel Italy Japan Norway Singapore Spain Taiwan United Kingdom United States View All |
NCT02445222 |
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis |
Multiple Sclerosis | Phase3 | France Germany Mexico Spain Ukraine United Kingdom United States View All |
NCT01892722 |
A Cross-sectional Study to Assess the Effectiveness and Safety of Ofatumumab (Kesimpta®) in Patients With Relapsing Multiple Sclerosis in the Spanish Clinical Practice |
Relapsing Forms of Multiple Sclerosis | Spain | NCT06251986 | |
Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC. |
Non-Small Cell Lung Carcinoma | Phase4 | India | NCT05110196 |
An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus |
Systemic Lupus Erythematosus, Lupus Nephritis | Phase1, Phase2 | Australia France Germany Spain Switzerland United States View All |
NCT05798117 |
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab |
Extensive Stage Small Cell Lung Cancer | Phase1, Phase2 | France Germany Spain United Kingdom United States View All |
NCT05142696 |